

* * * * * * * * * * * * * * * STN Columbus *

FILE 'HOME' ENTERED ON 23 NOV 1998

=> file uspatfull

=> s ((tumor? necros? factor?) or
tnf?)(5a)receptor?

. 24416 TUMOR?
7979 NECROS?
432703 FACTOR?
2469 TUMOR? NECROS? FACTOR?
(TUMOR?(W)NECROS?(W)FACTOR?)
2875 TNF?
35182 RECEPTOR?

L1 405 ((TUMOR? NECROS? FACTOR?) OR
TNF?)(5A)RECEPTOR?

=> d 1-20

L1 ANSWER 1 OF 405 USPATFULL
AN 1998:144233 USPATFULL
TI Nucleic acids molecules encoding
Caspase-8h and Caspase-8i
IN Hunter, John J., Cambridge, MA, United
States Shyjan, Andrew W., Nahant, MA, United
States Wong, Grace H. W., Brookline, MA,
United States
PA Millennium Pharmaceuticals, Inc.,
Cambridge, MA, United States
(U.S. corporation)
PI US 5837837 981117
AI US 97-807200 970227 (8)
DT Utility
LN.CNT 2079
INCL INCLM: 536/023.100
INCLS: 530/300.000; 530/350.000
NCL NCLM: 536/023.100
NCLS: 530/300.000; 530/350.000
IC [6]
ICM: C07H021-02
ICS: A61K038-00; C07K001-00
EXF 536/23.1; 530/350; 435/172.3;
435/69.1; 435/325; 424/93.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 405 USPATFULL
AN 1998:144213 USPATFULL
TI Tumor necrosis factor
receptor-II-associated protein kinase
and methods for its
use
IN Aggarwal, Bharat B., Houston, TX,
United States Darnay, Bryant G., Houston, TX, United
States
PA Research Development Foundation,
Carson City, NV, United States
(U.S. corporation)
PI US 5837817 981117
AI US 96-588604 960118 (8)
RLI Continuation-in-part of Ser. No. US
94-272005, filed on 7 Jul
1994, now abandoned
DT Utility
LN.CNT 953
INCL INCLM: 530/350.000
INCLS: 530/351.000; 435/194.000
NCL NCLM: 530/350.000

NCLS: 530/351.000; 435/194.000
IC [6]
ICM: C07K014-705
EXF 435/194; 530/350; 530/351
L1 ANSWER 3 OF 405 USPATFULL
AN 1998:144212 USPATFULL
TI Interleukin-2 receptor subunit
ectodomain fusion protein
comprising a leucine zipper domain
IN Ciardelli, Thomas L., Sharon, VT,
United States Johnson, Kirk, Moraga, CA, United
States PA Chiron Corporation, Emeryville, CA,
United States (U.S.
corporation)
Trustee of Dartmouth College, Hanover,
NH, United States (U.S.
corporation)
PI US 5837816 981117
AI US 95-474741 950607 (8)
RLI Continuation-in-part of Ser. No. US
95-438259, filed on 10 May
1995, now abandoned
DT Utility
LN.CNT 1970
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
IC [6]
ICM: C07K014-435
ICS: C07K014-705; C07K014-715;
C12N015-12
EXF 530/350; 435/69.1; 435/320.1;
435/240.2; 435/325; 435/7.1;
536/23.4; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L1 ANSWER 4 OF 405 USPATFULL
AN 1998:144102 USPATFULL
TI Amino-alcohol substituted cyclic
compounds
IN Kumar, Anil M., Seattle, WA, United
States Michnick, John, Seattle, WA, United
States Underiner, Gail E., Brier, WA, United
States Klein, J. Peter, Vashon Island, WA,
United States Rice, Glenn C., Seattle, WA, United
States PA Cell Therapeutics, Inc., Seattle, WA,
United States (U.S.
corporation)
PI US 5837703 981117
AI US 93-152650 931112 (8)
RLI Continuation-in-part of Ser. No. US
93-40820, filed on 31 Mar
1993, now abandoned
DT Utility
LN.CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800;
514/241.000; 514/242.000;
514/249.000; 514/256.000;
514/259.000; 514/263.000;
514/270.000; 514/274.000;
514/309.000; 514/312.000;

514/315.000; 514/348.000;
514/357.000; 514/374.000;
514/400.000; 514/425.000;
514/427.000; 540/467.000;
540/544.000; 544/216.000;
544/257.000; 544/272.000;
544/286.000; 544/301.000;
544/311.000; 544/335.000;
546/096.000; 546/141.000;
546/142.000; 546/157.000;
546/246.000; 546/296.000;
546/334.000; 548/215.000;
548/340.100; 548/485.000;
548/546.000; 548/561.000
NCL NCLM: 514/183.000
NCLS: 514/211.000; 514/228.800;
514/241.000; 514/242.000;
514/249.000; 514/256.000;
514/259.000; 514/263.000;
514/270.000; 514/274.000;
514/309.000; 514/312.000;
514/315.000; 514/348.000;
514/357.000; 514/374.000;
514/400.000; 514/425.000;
514/427.000; 540/467.000;
540/544.000; 544/216.000;
544/257.000; 544/272.000;
544/286.000; 544/301.000;
544/311.000; 544/335.000;
546/096.000; 546/141.000;
546/142.000; 546/157.000;
546/246.000; 546/296.000;
546/334.000; 548/215.000;
548/340.100; 548/485.000;
548/546.000; 548/561.000
IC [6]
ICM: A61K031-55
ICS: A61K031-515; A61K031-445;
A61K031-52
EXF 544/276; 544/272; 544/216; 544/257;
544/285; 544/286; 544/301;
544/311; 544/335; 514/263; 514/183;
514/211; 514/228.8; 514/241;
514/242; 514/249; 514/256; 514/259;
514/270; 514/274; 514/309;
514/312; 514/315; 514/348; 514/357;
514/374; 514/400; 514/418;
514/425; 514/427; 540/467; 540/544;
546/96; 546/141; 546/142;
546/157; 546/246; 546/296; 546/334;
548/215; 548/340.1; 548/485;
548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 405 USPATFULL
AN 1998:143939 USPATFULL
TI Expression of human multidrug
resistance genes and improved
selection of cells transduced with
such genes
IN McDonagh, Kevin T., Silver Spring, MD,
United States
Nienhuis, Arthur, Bethesda, MD, United
States
Tolstoshev, Paul, Potomac, MD, United
States
PA Genetic Therapy, Inc., Gaithersburg,
MD, United States (U.S.
corporation)
The United States of America as
represented by the Department of
Health and Human Services, Washington,
DC, United States (U.S.
government)
PI US 5837536 981117

AI US 96-583276 960105 (8)
RLI Continuation of Ser. No. US 94-332444,
filed on 31 Oct 1994, now
abandoned which is a continuation of
Ser. No. US 92-887712, filed
on 22 May 1992, now abandoned
DT Utility
LN.CNT 1231
INCL INCLM: 435/325.000
INCLS: 536/023.500; 435/069.100;
435/320.100
NCL NCLM: 435/325.000
NCLS: 536/023.500; 435/069.100;
435/320.100
IC [6]
ICM: C12N005-22
ICS: C12N015-12; C12N015-86
EXF 536/23.1; 435/69.1; 435/320.1;
435/240.2; 435/325
L1 ANSWER 6 OF 405 USPATFULL
AN 1998:143904 USPATFULL
TI Directed evolution of novel binding
proteins
IN Ladner, Robert Charles, Ijamsville,
MD, United States
Guterman, Sonia Kosow, Belmont, MA,
United States
Roberts, Bruce Lindsay, Milford, MA,
United States
Markland, William, Milford, MA, United
States
Ley, Arthur Charles, Newton, MA,
United States
Kent, Rachel Baribault, Boxborough,
MA, United States
PA Dyax, Corp., Cambridge, MA, United
States (U.S. corporation)
PI US 5837500 981117
AI US 95-415922 950403 (8)
RLI Continuation of Ser. No. US 93-9319,
filed on 26 Jan 1993, now
patented, Pat. No. US 5403484 which is
a division of Ser. No. US
91-664989, filed on 1 Mar 1991, now
patented, Pat. No. US 5223409
which is a continuation-in-part of
Ser. No. US 90-487063, filed on
2 Mar 1990, now abandoned which is a
continuation-in-part of Ser.
No. US 88-240160, filed on 2 Sep 1988,
now abandoned
DT Utility
LN.CNT 15973
INCL INCLM: 435/069.700
INCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
NCL NCLM: 435/069.700
NCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
IC [6]
ICM: C12N015-62
ICS: C07K019-00
EXF 435/69.7; 435/172.3; 530/350; 530/412;
536/23.4
L1 ANSWER 7 OF 405 USPATFULL
AN 1998:143875 USPATFULL
TI Method of recovering a biological
molecule from a recombinant
microorganism
IN Carlson, Peter S., Alexandria, VA,
United States
Quintero, Ernesto J., McLean, VA,
United States

Manyak, David M., Ellicott City, MD,
 United States
 Chmurny, Alan B., Frederick, MD,
 United States
 PA Oceanix Biosciences Corporation,
 Hanover, MD, United States (U.S.
 corporation)
 PI US 5837470 981117
 AI US 98-21984 980211
 RLI Division of Ser. No. US 96-766308,
 filed on 13 Dec 1996
 DT Utility
 LN.CNT 1493
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/172.300;
 435/172.200; 435/252.300
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/172.300;
 435/172.200; 435/252.300
 IC [6]
 ICM: C12Q001-68
 ICS: C12P021-02
 EXF 435/6; 435/69.1; 435/172.2; 435/172.3;
 435/252.3

L1 ANSWER 8 OF 405 USPATFULL
 AN 1998:139020 USPATFULL
 TI Chimeric viral receptor polypeptides
 IN Meruelo, Daniel, Scarborough, NY,
 United States
 Yoshimoto, Takayuki, Tokyo, Japan
 PA New York University, New York, NY,
 United States (U.S.
 corporation)
 PI US 5834589 981110
 AI US 93-132990 931007 (8)
 RLI Continuation-in-part of Ser. No. US
 93-84729, filed on 29 Jun
 1993, now abandoned which is a
 continuation-in-part of Ser. No. US
 92-899075, filed on 11 Jun 1992, now
 abandoned which is a
 continuation-in-part of Ser. No. US
 91-806178, filed on 13 Dec
 1991, now abandoned which is a
 continuation-in-part of Ser. No. US
 90-627950, filed on 14 Dec 1990, now
 abandoned
 DT Utility
 LN.CNT 3800
 INCL INCLM: 530/350.000
 INCLS: 530/387.300; 530/388.300;
 530/389.100; 530/826.000;
 435/171.300
 NCL NCLM: 530/350.000
 NCLS: 530/387.300; 530/388.300;
 530/389.100; 530/826.000;
 435/171.300
 IC [6]
 ICM: C12N015-00
 ICS: C12P021-08; C07K016-00; C07K014-
 00
 EXF 530/350; 530/387.3; 530/387.1;
 530/387.7

L1 ANSWER 9 OF 405 USPATFULL
 AN 1998:138917 USPATFULL
 TI Quinoline sulfonamides and their
 therapeutic use
 IN Dyke, Hazel Joan, Cambridge, United
 Kingdom
 Montana, John Gary, Cambridge, United
 Kingdom
 PA Chiroscience Limited, United Kingdom
 (non-U.S. corporation)

PI US 5834485 981110
 AI US 97-858969 970520 (8)
 PRAI GB 96-10506 960520
 GB 96-23234 961107
 GB 96-26883 961224
 GB 97-8071 970422
 DT Utility
 LN.CNT 732
 INCL INCLM: 514/311.000
 INCLS: 514/312.000; 514/313.000;
 514/314.000; 546/153.000;
 546/155.000; 546/156.000;
 546/157.000; 546/159.000;
 546/160.000; 546/168.000;
 546/169.000; 546/170.000;
 546/172.000
 NCL NCLM: 514/311.000
 NCLS: 514/312.000; 514/313.000;
 514/314.000; 546/153.000;
 546/155.000; 546/156.000;
 546/157.000; 546/159.000;
 546/160.000; 546/168.000;
 546/169.000; 546/170.000;
 546/172.000
 IC [6]
 ICM: C07D215-36
 ICS: A61K031-47
 EXF 546/154; 546/155; 546/156; 546/157;
 546/160; 546/162; 546/172;
 514/311; 514/312; 514/313; 514/314

L1 ANSWER 10 OF 405 USPATFULL
 AN 1998:138868 USPATFULL
 TI Inhibition of TNF-.alpha. pleiotropic
 and cytotoxic effects
 IN Slesarev, Vladimir I., 20 Colebrook
 La., Conroe, TX, United States
 77304
 PI US 5834435 981110
 AI US 96-757477 961127 (8)
 DT Utility
 LN.CNT 611
 INCL INCLM: 514/019.000
 INCLS: 514/008.000; 514/016.000;
 514/921.000; 514/885.000;
 530/322.000
 NCL NCLM: 514/019.000
 NCLS: 514/008.000; 514/016.000;
 514/921.000; 514/885.000;
 530/322.000
 IC [6]
 ICM: A61K038-05
 EXF 514/19; 514/8; 514/16; 514/921;
 514/885; 530/322

L1 ANSWER 11 OF 405 USPATFULL
 AN 1998:138853 USPATFULL
 TI Chemokine binding protein and methods
 of use therefor
 IN McFadden, Grant, Edmonton, Canada
 Lucas, Alexandra, Edmonton, Canada
 PA The John P. Robarts Institute, London,
 Canada (non-U.S.
 corporation)
 PI US 5834419 981110
 AI US 96-634924 960419 (8)
 RLI Continuation-in-part of Ser. No. US
 95-424850, filed on 19 Apr
 1995, now abandoned
 DT Utility
 LN.CNT 1033
 INCL INCLM: 514/002.000
 INCLS: 514/008.000; 514/012.000;
 530/350.000; 424/084.000
 NCL NCLM: 514/002.000

NCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
IC [6]
ICM: C61K038-16
ICS: C07K014-065
EXF 530/350; 514/2; 514/8; 514/12; 424/84

L1 ANSWER 12 OF 405 USPATFULL
AN 1998:138709 USPATFULL
TI Regulated apoptosis
IN Crabtree, Gerald R., Woodside, CA,
United States
Schreiber, Stuart L., Cambridge, MA,
United States
Spencer, David M., Los Altos, CA,
United States
Wandless, Thomas J., Cambridge, MA,
United States
Belshaw, Peter, Somerville, MA, United
States
PA President & Fellows of Harvard
College, Cambridge, MA, United
States (U.S. corporation)
Board of Trustees of Leland Stanford
Jr. University, Stanford, CA,
United States (U.S. corporation)
PI US 5834266 981110
AI US 94-292597 940818 (8)
RLI Continuation-in-part of Ser. No. US
94-179143, filed on 7 Jan
1994, now abandoned And Ser. No. US
94-179748, filed on 7 Jan 1994
which is a continuation-in-part of
Ser. No. US 93-92977, filed on
16 Jul 1993, now abandoned which is a
continuation-in-part of Ser.
No. US 93-17931, filed on 12 Feb 1993,
now abandoned , said Ser.
No. US -179143 which is a
continuation-in-part of Ser. No. US
93-93499, filed on 16 Jul 1993
DT Utility
LN.CNT 5242
INCL INCLM: 435/172.300
INCLS: 435/320.100; 435/325.000;
435/366.000; 536/234.000
NCL NCLM: 435/172.300
NCLS: 435/320.100; 435/325.000;
435/366.000; 536/234.000
IC [6]
ICM: C12N015-62
ICS: C12N015-63; C12N015-79; C12N005-
10
EXF 424/93.21; 514/44; 435/69.7;
435/240.2; 435/320.1; 435/23.4;
435/23.5; 435/325; 435/366; 435/372.3;
435/172.3; 536/23.4;
536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 405 USPATFULL
AN 1998:138693 USPATFULL
TI Method for identifying active domains
and amino acid residues in
polypeptides and hormone variants
IN Wells, James A., Burlingame, CA,
United States
Cunningham, Brian C., Piedmont, CA,
United States
PA Genentech, Inc., South San Francisco,
CA, United States (U.S.
corporation)
PI US 5834250 981110
AI US 97-903398 970630 (8)

RLI Continuation of Ser. No. US 95-483039,
filed on 6 Jun 1995, now
patented, Pat. No. US 5766854 which is
a continuation of Ser. No.
US 94-190723, filed on 2 Feb 1994, now
patented, Pat. No. US
5580723 which is a continuation of
Ser. No. US 92-960227, filed on
13 Oct 1992, now abandoned which is a
continuation of Ser. No. US
92-875204, filed on 27 Apr 1992, now
abandoned which is a
continuation of Ser. No. US 89-428066,
filed on 26 Oct 1989, now
abandoned which is a continuation-in-
part of Ser. No. US
88-264611, filed on 28 Oct 1988, now
abandoned
DT Utility
LN.CNT 3240
INCL INCLM: 435/007.100
INCLS: 435/004.000; 435/006.000;
436/501.000; 530/300.000;
530/326.000
NCL NCLM: 435/007.100
NCLS: 435/004.000; 435/006.000;
436/501.000; 530/300.000;
530/326.000
IC [6]
ICM: G01N033-53
ICS: G01N033-566
EXF 435/7.1; 435/4; 435/6; 435/69.1;
435/71.1; 436/501; 530/300;
530/326; 530/350; 530/387.1;
530/388.1; 530/399; 530/806; 530/808

L1 ANSWER 14 OF 405 USPATFULL
AN 1998:138593 USPATFULL
TI Composition of photoconductive layer
for a color display panel
IN Kim, Min Ho, Suwon-si, Korea, Republic
of
Park, Wan Woo, Suwon-si, Korea,
Republic of
PA Samsung Display Devices Co., Ltd.,
Suwon-si, Korea, Republic of
(non-U.S. corporation)
PI US 5834144 981110
AI US 97-935443 970923 (8)
PRAI KR 96-61603 961204
KR 96-61606 961204
DT Utility
LN.CNT 378
INCL INCLM: 430/028.000
NCL NCLM: 430/028.000
IC [6]
ICM: G03C005-00
EXF 430/28; 430/58; 430/59

L1 ANSWER 15 OF 405 USPATFULL
AN 1998:135173 USPATFULL
TI Interleukin-8 anti-peptide antibodies
IN Schraufstatter, Ingrid U., San Diego,
CA, United States
Cochrane, Charles G., La Jolla, CA,
United States
PA The Scripps Research Institute, La
Jolla, CA, United States (U.S.
corporation)
PI US 5831032 981103
AI US 96-643515 960506 (8)
RLI Division of Ser. No. US 94-342348,
filed on 21 Nov 1994, now
abandoned which is a continuation of
Ser. No. US 91-755824, filed

on 6 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 90-581673, filed on 12 Sep 1990, now abandoned

DT Utility

LN.CNT 1372

INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/388.230;
530/389.200; 530/326.000;
530/412.000; 530/413.000

NCL NCLM: 530/387.900
NCLS: 530/388.100; 530/388.230;
530/389.200; 530/326.000;
530/412.000; 530/413.000

IC [6]
ICM: C07K016-24
EXF 560/387.1; 560/388.1; 560/388.25;
560/389.2; 560/387.9; 560/326;
514/412; 514/413

L1 ANSWER 16 OF 405 USPATFULL
AN 1998:135151 USPATFULL
TI Human receptor for interleukin-12
IN Chua, Anne On, Wayne, NJ, United States
Gubler, Ulrich Andreas, Glen Ridge, NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 5831007 981103
AI US 95-419652 950411 (8)
RLI Division of Ser. No. US 94-248532, filed on 31 May 1994, now patented, Pat. No. US 5536657 which is a continuation-in-part of Ser. No. US 93-94713, filed on 19 Jul 1993, now abandoned

DT Utility

LN.CNT 1929

INCL INCLM: 530/350.000
INCLS: 530/351.000; 514/002.000;
514/008.000

NCL NCLM: 530/350.000
NCLS: 530/351.000; 514/002.000;
514/008.000

IC [6]
ICM: C07K014-715
EXF 514/2; 514/8; 530/350; 530/351

L1 ANSWER 17 OF 405 USPATFULL
AN 1998:135009 USPATFULL
TI Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
IN Gray, Beulah H., St. Paul, MN, United States
Haseman, Judith R., Eagan, MN, United States
Mayo, Kevin H., Minnetonka, MN, United States
PA Regents of the University of Minnesota, Minneapolis, MN, United States (U.S. corporation)
PI US 5830860 981103
AI US 96-653632 960524 (8)
RLI Continuation-in-part of Ser. No. US 94-218026, filed on 24 Mar 1994

DT Utility

LN.CNT 3083

INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;

435/069.700
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;
435/069.700

IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-17
EXF 514/12; 514/13; 514/14; 514/15;
514/21; 435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 405 USPATFULL
AN 1998:134631 USPATFULL
TI Fas antagonists and uses thereof
IN Lynch, David H., Bainbridge Island, WA, United States
Alderson, Mark R., Bainbridge Island, WA, United States
PA Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PI US 5830469 981103
AI US 95-429499 950426 (8)
RLI Continuation-in-part of Ser. No. US 94-322805, filed on 13 Oct 1994, now patented, Pat. No. US 5620889 which is a continuation-in-part of Ser. No. US 93-159003, filed on 29 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 93-136817, filed on 14 Oct 1993, now abandoned

DT Utility

LN.CNT 1993

INCL INCLM: 424/144.100
INCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000

NCL NCLM: 424/144.100
NCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000

IC [6]
ICM: A16K039-395
ICS: A16K035-12; C07K016-18; C12N005-12
EXF 424/141.1; 424/154.1; 424/143.1;
424/140.1; 424/144.1; 424/155.1;
424/156.1; 424/153.1; 530/388.1;
530/387.1; 530/388.73;
530/388.75; 530/388.2; 530/388.22;
530/388.23; 530/388.24; 435/332

L1 ANSWER 19 OF 405 USPATFULL
AN 1998:134626 USPATFULL
TI Regulated transcription of targeted genes and other biological events
IN Crabtree, Gerald R., Woodside, CA, United States
Schreiber, Stuart L., Cambridge, MA, United States
Spencer, David M., Los Altos, CA, United States
Wandless, Thomas J., Cambridge, MA, United States
Belshaw, Peter, Cambridge, MA, United States
PA President & Fellows of Harvard College, Cambridge, MA, United

States (U.S. corporation)
 Board of Trustees of Leland S.
 Stanford, Jr. University, Stanford,
 CA, United States (U.S. corporation)
 PI US 5830462 981103
 AI US 95-478386 950607 (8)
 RLI Division of Ser. No. US 95-388653,
 filed on 14 Feb 1995 And a
 continuation-in-part of Ser. No. US
 94-292597, filed on 18 Aug
 1994 which is a continuation-in-part
 of Ser. No. US 94-179748,
 filed on 7 Jan 1994, now abandoned
 which is a continuation-in-part
 of Ser. No. US 93-92977, filed on 16
 Jul 1993, now abandoned which
 is a continuation-in-part of Ser. No.
 US 93-17931, filed on 12 Feb
 1993, now abandoned , said Ser. No. US
 -388653 which is a
 continuation-in-part of Ser. No. US
 94-196043, filed on 11 Feb
 1994 which is a continuation-in-part
 of Ser. No. US -179748
 which is a continuation-in-part of
 Ser. No. US -92977 which is a
 continuation-in-part of Ser. No. US
 -17931
 DT Utility
 LN.CNT 4524
 INCL INCLM: 424/093.210
 INCLS: 435/172.300; 514/044.000
 NCL NCLM: 424/093.210
 NCLS: 435/172.300; 514/044.000
 IC [6]
 ICM: C12N015-63
 ICS: A61K031-70; A61K048-00
 EXF 435/69.1; 435/69.7; 435/240.2;
 435/320.1; 435/172.3; 935/34;
 935/36; 935/70; 935/71; 424/93.21;
 514/44

L1 ANSWER 20 OF 405 USPATFULL
 AN 1998:134612 USPATFULL
 TI Compositions and methods for the
 treatment of tumors
 IN Vehar, Gordon A., San Carlos, CA,
 United States
 PA Genentech, Inc., South San Francisco,
 CA, United States (U.S.
 corporation)
 PI US 5830448 981103
 AI US 95-470777 950606 (8)
 RLI Division of Ser. No. US 94-260850,
 filed on 16 Jun 1994
 DT Utility
 LN.CNT 1698
 INCL INCLM: 424/085.200
 INCLS: 514/002.000; 530/351.000;
 530/381.000; 424/085.500;
 424/085.100
 NCL NCLM: 424/085.200
 NCLS: 514/002.000; 530/351.000;
 530/381.000; 424/085.500;
 424/085.100
 IC [6]
 ICM: A61K045-05
 ICS: A61K038-00
 EXF 514/2; 530/351; 530/381; 424/85.2;
 424/85.5; 424/85.1

=> s 11 and (clon? or cdna?)

23616 CLON?
10407 CDNA?

L2 292 L1 AND (CLON? OR CDNA?)
 => d 1-20

L2 ANSWER 1 OF 292 USPATFULL
 AN 1998:144233 USPATFULL
 TI Nucleic acids molecules encoding
 Caspase-8h and Caspase-8i
 IN Hunter, John J., Cambridge, MA, United
 States
 Shyjan, Andrew W., Nahant, MA, United
 States
 Wong, Grace H. W., Brookline, MA,
 United States
 PA Millennium Pharmaceuticals, Inc.,
 Cambridge, MA, United States
 (U.S. corporation)
 PI US 5837837 981117
 AI US 97-807200 970227 (8)
 DT Utility
 LN.CNT 2079
 INCL INCLM: 536/023.100
 INCLS: 530/300.000; 530/350.000
 NCL NCLM: 536/023.100
 NCLS: 530/300.000; 530/350.000
 IC [6]
 ICM: C07H021-02
 ICS: A61K038-00; C07K001-00
 EXF 536/23.1; 530/350; 435/172.3;
 435/69.1; 435/325; 424/93.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 292 USPATFULL
 AN 1998:144213 USPATFULL
 TI Tumor necrosis factor
 receptor-II-associated protein kinase
 and methods for its
 use
 IN Aggarwal, Bharat B., Houston, TX,
 United States
 Darnay, Bryant G., Houston, TX, United
 States
 PA Research Development Foundation,
 Carson City, NV, United States
 (U.S. corporation)
 PI US 5837817 981117
 AI US 96-588604 960118 (8)
 RLI Continuation-in-part of Ser. No. US
 94-272005, filed on 7 Jul
 1994, now abandoned
 DT Utility
 LN.CNT 953
 INCL INCLM: 530/350.000
 INCLS: 530/351.000; 435/194.000
 NCL NCLM: 530/350.000
 NCLS: 530/351.000; 435/194.000
 IC [6]
 ICM: C07K014-705
 EXF 435/194; 530/350; 530/351

L2 ANSWER 3 OF 292 USPATFULL
 AN 1998:144212 USPATFULL
 TI Interleukin-2 receptor subunit
 ectodomain fusion protein
 comprising a leucine zipper domain
 IN Ciardelli, Thomas L., Sharon, VT,
 United States
 Johnson, Kirk, Moraga, CA, United
 States
 PA Chiron Corporation, Emeryville, CA,
 United States (U.S.
 corporation)

Trustee of Dartmouth College, Hanover,
NH, United States (U.S.
corporation)
PI US 5837816 981117.
AI US 95-474741 950607 (8)
RLI Continuation-in-part of Ser. No. US
95-438259, filed on 10 May
1995, now abandoned
DT Utility
LN.CNT 1970
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
IC [6]
ICM: C07K014-435
ICS: C07K014-705; C07K014-715;
C12N015-12
EXF 530/350; 435/69.1; 435/320.1;
435/240.2; 435/325; 435/7.1;
536/23.4; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2 ANSWER 4 OF 292 USPATFULL
AN 1998:144102 USPATFULL
TI Amino-alcohol substituted cyclic
compounds
IN Kumar, Anil M., Seattle, WA, United
States
Michnick, John, Seattle, WA, United
States
Underiner, Gail E., Brier, WA, United
States
Klein, J. Peter, Vashon Island, WA,
United States
Rice, Glenn C., Seattle, WA, United
States
PA Cell Therapeutics, Inc., Seattle, WA,
United States (U.S.
corporation)
PI US 5837703 981117
AI US 93-152650 931112 (8)
RLI Continuation-in-part of Ser. No. US
93-40820, filed on 31 Mar
1993, now abandoned
DT Utility
LN.CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800;
514/241.000; 514/242.000;
514/249.000; 514/256.000;
514/259.000; 514/263.000;
514/270.000; 514/274.000;
514/309.000; 514/312.000;
514/315.000; 514/348.000;
514/357.000; 514/374.000;
514/400.000; 514/425.000;
514/427.000; 540/467.000;
540/544.000; 544/216.000;
544/257.000; 544/272.000;
544/286.000; 544/301.000;
544/311.000; 544/335.000;
546/096.000; 546/141.000;
546/142.000; 546/157.000;
546/246.000; 546/296.000;
546/334.000; 548/215.000;
548/340.100; 548/485.000;
548/546.000; 548/561.000
NCL NCLM: 514/183.000
NCLS: 514/211.000; 514/228.800;
514/241.000; 514/242.000;

514/259.000; 514/263.000;
514/270.000; 514/274.000;
514/309.000; 514/312.000;
514/315.000; 514/348.000;
514/357.000; 514/374.000;
514/400.000; 514/425.000;
514/427.000; 540/467.000;
540/544.000; 544/216.000;
544/257.000; 544/272.000;
544/286.000; 544/301.000;
544/311.000; 544/335.000;
546/096.000; 546/141.000;
546/142.000; 546/157.000;
546/246.000; 546/296.000;
546/334.000; 548/215.000;
548/340.100; 548/485.000;
548/546.000; 548/561.000
IC [6]
ICM: A61K031-55
ICS: A61K031-515; A61K031-445;
A61K031-52
EXF 544/276; 544/272; 544/216; 544/257;
544/285; 544/286; 544/301;
544/311; 544/335; 514/263; 514/183;
514/211; 514/228.8; 514/241;
514/242; 514/249; 514/256; 514/259;
514/270; 514/274; 514/309;
514/312; 514/315; 514/348; 514/357;
514/374; 514/400; 514/418;
514/425; 514/427; 540/467; 540/544;
546/96; 546/141; 546/142;
546/157; 546/246; 546/296; 546/334;
548/215; 548/340.1; 548/485;
548/546; 548/561
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2 ANSWER 5 OF 292 USPATFULL
AN 1998:143939 USPATFULL
TI Expression of human multidrug
resistance genes and improved
selection of cells transduced with
such genes
IN McDogagh, Kevin T., Silver Spring, MD,
United States
Nienhuis, Arthur, Bethesda, MD, United
States
Tolstoshev, Paul, Potomac, MD, United
States
PA Genetic Therapy, Inc., Gaithersburg,
MD, United States (U.S.
corporation)
The United States of America as
represented by the Department of
Health and Human Services, Washington,
DC, United States (U.S.
government)
PI US 5837536 981117
AI US 96-583276 960105 (8)
RLI Continuation of Ser. No. US 94-332444,
filed on 31 Oct 1994, now
abandoned which is a continuation of
Ser. No. US 92-887712, filed
on 22 May 1992, now abandoned
DT Utility
LN.CNT 1231
INCL INCLM: 435/325.000
INCLS: 536/023.500; 435/069.100;
435/320.100
NCL NCLM: 435/325.000
NCLS: 536/023.500; 435/069.100;
435/320.100
IC [6]
ICM: C12N005-22
ICS: C12N015-12; C12N015-86

EXF 536/23.1; 435/69.1; 435/320.1;
435/240.2; 435/325

L2 ANSWER 6 OF 292 USPATFULL
AN 1998:143904 USPATFULL
TI Directed evolution of novel binding
proteins
IN Ladher, Robert Charles, Ijamsville,
MD, United States
Guterman, Sonia Kosow, Belmont, MA,
United States
Roberts, Bruce Lindsay, Milford, MA,
United States
Markland, William, Milford, MA, United
States
Ley, Arthur Charles, Newton, MA,
United States
Kent, Rachel Baribault, Boxborough,
MA, United States
PA Dyax, Corp., Cambridge, MA, United
States (U.S. corporation)
PI US 5837500 981117
AI US 95-415922 950403 (8)
RLI Continuation of Ser. No. US 93-9319,
filed on 26 Jan 1993, now
patented, Pat. No. US 5403484 which is
a division of Ser. No. US
91-664989, filed on 1 Mar 1991, now
patented, Pat. No. US 5223409
which is a continuation-in-part of
Ser. No. US 90-487063, filed on
2 Mar 1990, now abandoned which is a
continuation-in-part of Ser.
No. US 88-240160, filed on 2 Sep 1988,
now abandoned
DT Utility
LN.CNT 15973
INCL INCLM: 435/069.700
INCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
NCL NCLM: 435/069.700
NCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
IC [6]
ICM: C12N015-62
ICS: C07K019-00
EXF 435/69.7; 435/172.3; 530/350; 530/412;
536/23.4

L2 ANSWER 7 OF 292 USPATFULL
AN 1998:143875 USPATFULL
TI Method of recovering a biological
molecule from a recombinant
microorganism
IN Carlson, Peter S., Alexandria, VA,
United States
Quintero, Ernesto J., McLean, VA,
United States
Manyak, David M., Ellicott City, MD,
United States
Chmurny, Alan B., Frederick, MD,
United States
PA Oceanix Biosciences Corporation,
Hanover, MD, United States (U.S.
corporation)
PI US 5837470 981117
AI US 98-21984 980211
RLI Division of Ser. No. US 96-766308,
filed on 13 Dec 1996
DT Utility
LN.CNT 1493
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
IC [6]
ICM: C12Q001-68
ICS: C12P021-02
EXF 435/6; 435/69.1; 435/172.2; 435/172.3;
435/252.3

L2 ANSWER 8 OF 292 USPATFULL
AN 1998:139020 USPATFULL
TI Chimeric viral receptor polypeptides
IN Meruelo, Daniel, Scarborough, NY,
United States
Yoshimoto, Takayuki, Tokyo, Japan
PA New York University, New York, NY,
United States (U.S.
corporation)
PI US 5834589 981110
AI US 93-132990 931007 (8)
RLI Continuation-in-part of Ser. No. US
93-84729, filed on 29 Jun
1993, now abandoned which is a
continuation-in-part of Ser. No. US
92-899075, filed on 11 Jun 1992, now
abandoned which is a
continuation-in-part of Ser. No. US
91-806178, filed on 13 Dec
1991, now abandoned which is a
continuation-in-part of Ser. No. US
90-627950, filed on 14 Dec 1990, now
abandoned
DT Utility
LN.CNT 3800
INCL INCLM: 530/350.000
INCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300
NCL NCLM: 530/350.000
NCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300
IC [6]
ICM: C12N015-00
ICS: C12P021-08; C07K016-00; C07K014-
00
EXF 530/350; 530/387.3; 530/387.1;
530/387.7

L2 ANSWER 9 OF 292 USPATFULL
AN 1998:138853 USPATFULL
TI Chemokine binding protein and methods
of use therefor
IN McFadden, Grant, Edmonton, Canada
Lucas, Alexandra, Edmonton, Canada
PA The John P. Robarts Institute, London,
Canada (non-U.S.
corporation)
PI US 5834419 981110
AI US 96-634924 960419 (8)
RLI Continuation-in-part of Ser. No. US
95-424850, filed on 19 Apr
1995, now abandoned
DT Utility
LN.CNT 1033
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
NCL NCLM: 514/002.000
NCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
IC [6]
ICM: C61K038-16
ICS: C07K014-065
EXF 530/350; 514/2; 514/8; 514/12; 424/84

L2 ANSWER 10 OF 292 USPATFULL
AN 1998:138709 USPATFULL
TI Regulated apoptosis.
IN Crabtree, Gerald R., Woodside, CA,
United States
Schreiber, Stuart L., Cambridge, MA,
United States
Spencer, David M., Los Altos, CA,
United States
Wandless, Thomas J., Cambridge, MA,
United States
Belshaw, Peter, Somerville, MA, United
States
PA President & Fellows of Harvard
College, Cambridge, MA, United
States (U.S. corporation)
Board of Trustees of Leland Stanford
Jr. University, Stanford, CA,
United States (U.S. corporation)
PI US 5834266 981110
AI US 94-292597 940818 (8)
RLI Continuation-in-part of Ser. No. US
94-179143, filed on 7 Jan
1994, now abandoned And Ser. No. US
94-179748, filed on 7 Jan 1994
which is a continuation-in-part of
Ser. No. US 93-92977, filed on
16 Jul 1993, now abandoned which is a
continuation-in-part of Ser.
No. US 93-17931, filed on 12 Feb 1993,
now abandoned , said Ser.
No. US -179143 which is a
continuation-in-part of Ser. No. US
93-93499, filed on 16 Jul 1993
DT Utility
LN.CNT 5242
INCL INCLM: 435/172.300
INCLS: 435/320.100; 435/325.000;
435/366.000; 536/234.000
NCL NCLM: 435/172.300
NCLS: 435/320.100; 435/325.000;
435/366.000; 536/234.000
IC [6]
ICM: C12N015-62
ICS: C12N015-63; C12N015-79; C12N005-
10
EXF 424/93.21; 514/44; 435/69.7;
435/240.2; 435/320.1; 435/23.4;
435/23.5; 435/325; 435/366; 435/372.3;
435/172.3; 536/23.4;
536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 292 USPATFULL
AN 1998:138693 USPATFULL
TI Method for identifying active domains
and amino acid residues in
polypeptides and hormone variants
IN Wells, James A., Burlingame, CA,
United States
Cunningham, Brian C., Piedmont, CA,
United States
PA Genentech, Inc., South San Francisco,
CA, United States (U.S.
corporation)
PI US 5834250 981110
AI US 97-903398 970630 (8)
RLI Continuation of Ser. No. US 95-483039,
filed on 6 Jun 1995, now
patented, Pat. No. US 5766854 which is
a continuation of Ser. No.
US 94-190723, filed on 2 Feb 1994, now
patented, Pat. No. US
5580723 which is a continuation of
Ser. No. US 92-960227, filed on

13 Oct 1992, now abandoned which is a
continuation of Ser. No. US
92-875204, filed on 27 Apr 1992, now
abandoned which is a
continuation of Ser. No. US 89-428066,
filed on 26 Oct 1989, now
abandoned which is a continuation-in-
part of Ser. No. US
88-264611, filed on 28 Oct 1988, now
abandoned
DT Utility
LN.CNT 3240
INCL INCLM: 435/007.100
INCLS: 435/004.000; 435/006.000;
436/501.000; 530/300.000;
530/326.000
NCL NCLM: 435/007.100
NCLS: 435/004.000; 435/006.000;
436/501.000; 530/300.000;
530/326.000
IC [6]
ICM: G01N033-53
ICS: G01N033-566
EXF 435/7.1; 435/4; 435/6; 435/69.1;
435/71.1; 436/501; 530/300;
530/326; 530/350; 530/387.1;
530/388.1; 530/399; 530/806; 530/808
L2 ANSWER 12 OF 292 USPATFULL
AN 1998:135173 USPATFULL
TI Interleukin-8 anti-peptide antibodies
IN Schraufstatter, Ingrid U., San Diego,
CA, United States
Cochrane, Charles G., La Jolla, CA,
United States
PA The Scripps Research Institute, La
Jolla, CA, United States (U.S.
corporation)
PI US 5831032 981103
AI US 96-643515 960506 (8)
RLI Division of Ser. No. US 94-342348,
filed on 21 Nov 1994, now
abandoned which is a continuation of
Ser. No. US 91-755824, filed
on 6 Sep 1991, now abandoned which is
a continuation-in-part of
Ser. No. US 90-581673, filed on 12 Sep
1990, now abandoned
DT Utility
LN.CNT 1372
INCL INCLM: 530/387.900
INCLS: 530/388.100; 530/388.230;
530/389.200; 530/326.000;
530/412.000; 530/413.000
NCL NCLM: 530/387.900
NCLS: 530/388.100; 530/388.230;
530/389.200; 530/326.000;
530/412.000; 530/413.000
IC [6]
ICM: C07K016-24
EXF 560/387.1; 560/388.1; 560/388.25;
560/389.2; 560/387.9; 560/326;
514/412; 514/413
L2 ANSWER 13 OF 292 USPATFULL
AN 1998:135151 USPATFULL
TI Human receptor for interleukin-12
IN Chua, Anne On, Wayne, NJ, United
States
Gubler, Ulrich Andreas, Glen Ridge,
NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ,
United States (U.S.
corporation)
PI US 5831007 981103

AI US 95-419652 950411 (8)
RLI Division of Ser. No. US 94-248532,
filed on 31 May 1994, now
patented, Pat. No. US 5536657 which is
a continuation-in-part of
Ser. No. US 93-94713, filed on 19 Jul
1993, now abandoned
DT Utility
LN.CNT 1929
INCL INCLM: 530/350.000
INCLS: 530/351.000; 514/002.000;
514/008.000
NCL NCLM: 530/350.000
NCLS: 530/351.000; 514/002.000;
514/008.000
IC [6]
ICM: C07K014-715
EXF 514/2; 514/8; 530/350; 530/351

L2 ANSWER 14 OF 292 USPATFULL
AN 1998:135009 USPATFULL
TI Peptides with bactericidal activity
and endotoxin neutralizing
activity for gram negative bacteria
and methods for their use
IN Gray, Beulah H., St. Paul, MN, United
States
Haseman, Judith R., Eagan, MN, United
States
Mayo, Kevin H., Minnetonka, MN, United
States
PA Regents of the University of
Minnesota, Minneapolis, MN, United
States (U.S. corporation)
PI US 5830860 981103
AI US 96-653632 960524 (8)
RLI Continuation-in-part of Ser. No. US
94-218026, filed on 24 Mar
1994
DT Utility
LN.CNT 3083
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;
435/069.700
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;
435/069.700
IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-17
EXF 514/12; 514/13; 514/14; 514/15;
514/21; 435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 292 USPATFULL
AN 1998:134631 USPATFULL
TI Fas antagonists and uses thereof
IN Lynch, David H., Bainbridge Island,
WA, United States
Alderson, Mark R., Bainbridge Island,
WA, United States
PA Immunex Corporation, Seattle, WA,
United States (U.S. corporation)
PI US 5830469 981103
AI US 95-429499 950426 (8)
RLI Continuation-in-part of Ser. No. US
94-322805, filed on 13 Oct
1994, now patented, Pat. No. US
5620889 which is a
continuation-in-part of Ser. No. US
93-159003, filed on 29 Nov
1993, now abandoned which is a
continuation-in-part of Ser. No. US

93-136817, filed on 14 Oct 1993, now
abandoned
DT Utility
LN.CNT 1993
INCL INCLM: 424/144.100
INCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000
NCL NCLM: 424/144.100
NCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000
IC [6]
ICM: A16K039-395
ICS: A16K035-12; C07K016-18; C12N005-
12
EXF 424/141.1; 424/154.1; 424/143.1;
424/140.1; 424/144.1; 424/155.1;
424/156.1; 424/153.1; 530/388.1;
530/387.1; 530/388.73;
530/388.75; 530/388.2; 530/388.22;
530/388.23; 530/388.24; 435/332
L2 ANSWER 16 OF 292 USPATFULL
AN 1998:134626 USPATFULL
TI Regulated transcription of targeted
genes and other biological
events
IN Crabtree, Gerald R., Woodside, CA,
United States
Schreiber, Stuart L., Cambridge, MA,
United States
Spencer, David M., Los Altos, CA,
United States
Wandless, Thomas J., Cambridge, MA,
United States
Belshaw, Peter, Cambridge, MA, United
States
PA President & Fellows of Harvard
College, Cambridge, MA, United
States (U.S. corporation)
Board of Trustees of Leland S.
Stanford, Jr. University, Stanford,
CA, United States (U.S. corporation)
PI US 5830462 981103
AI US 95-478386 950607 (8)
RLI Division of Ser. No. US 95-388653,
filed on 14 Feb 1995 And a
continuation-in-part of Ser. No. US
94-292597, filed on 18 Aug
1994 which is a continuation-in-part
of Ser. No. US 94-179748,
filed on 7 Jan 1994, now abandoned
which is a continuation-in-part
of Ser. No. US 93-92977, filed on 16
Jul 1993, now abandoned which
is a continuation-in-part of Ser. No.
US 93-17931, filed on 12 Feb
1993, now abandoned , said Ser. No. US
-388653 which is a
continuation-in-part of Ser. No. US
94-196043, filed on 11 Feb
1994 which is a continuation-in-part
of Ser. No. US -179748
which is a continuation-in-part of
Ser. No. US -92977 which is a
continuation-in-part of Ser. No. US
-17931
DT Utility
LN.CNT 4524
INCL INCLM: 424/093.210

INCLS: 435/172.300; 514/044.000
 NCL NCLM: 424/093.210
 NCLS: 435/172.300; 514/044.000
 IC [6]
 ICM: C12N015-63
 ICS: A61K031-70; A61K048-00
 EXF 435/69.1; 435/69.7; 435/240.2;
 435/320.1; 435/172.3; 935/34;
 935/36; 935/70; 935/71; 424/93.21;
 514/44
 L2 ANSWER 17 OF 292 USPATFULL
 AN 1998:134612 USPATFULL
 TI Compositions and methods for the treatment of tumors
 IN Vehar, Gordon A., San Carlos, CA, United States
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
 PI US 5830448 981103
 AI US 95-470777 950606 (8)
 RLI Division of Ser. No. US 94-260850, filed on 16 Jun 1994
 DT Utility
 LN.CNT 1698
 INCL INCLM: 424/085.200
 INCLS: 514/002.000; 530/351.000;
 530/381.000; 424/085.500;
 424/085.100
 NCL NCLM: 424/085.200
 NCLS: 514/002.000; 530/351.000;
 530/381.000; 424/085.500;
 424/085.100
 IC [6]
 ICM: A61K045-05
 ICS: A61K038-00
 EXF 514/2; 530/351; 530/381; 424/85.2;
 424/85.5; 424/85.1
 L2 ANSWER 18 OF 292 USPATFULL
 AN 1998:128378 USPATFULL
 TI Human stromelysin-1 promoter
 IN Borden, Paula Ann, Palo Alto, CA, United States
 Heller, Renu Anand, Stanford, CA, United States
 PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)
 PI US 5824794 981020
 AI US 94-362706 941223 (8)
 DT Utility
 LN.CNT 812
 INCL INCLM: 536/024.100
 INCLS: 435/172.300; 435/320.100;
 435/325.000; 435/366.000;
 435/252.300; 536/023.500
 NCL NCLM: 536/024.100
 NCLS: 435/252.300; 435/320.100;
 435/325.000; 435/366.000;
 536/023.500
 IC [6]
 ICM: C07H021-04
 ICS: C12N005-16; C12N015-12; C12N015-85
 EXF 514/44; 536/23.1; 536/24.1; 536/23.5;
 435/320.1; 435/240.2; 435/6;
 435/252.3; 435/366; 435/172.3;
 435/325; 424/93.21
 L2 ANSWER 19 OF 292 USPATFULL
 AN 1998:128265 USPATFULL
 TI Substituted amino alcohol compounds

IN Klein, J. Peter, Vashon, WA, United States
 Underiner, Gail E., Brier, WA, United States
 Kumar, Anil M., Seattle, WA, United States
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 5824677 981020
 AI US 95-474816 950607 (8)
 RLI Division of Ser. No. US 94-303842, filed on 8 Sep 1994, now patented, Pat. No. US 5641783 which is a continuation-in-part of Ser. No. US 93-152650, filed on 12 Nov 1993, now patented, Pat. No. US 5801181 And Ser. No. US 93-164081, filed on 8 Dec 1993, now patented, Pat. No. US 5470878 , said Ser. No. US -152650 And Ser. No. US -164081 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 93-40820, filed on 31 Mar 1993, now abandoned
 DT Utility
 LN.CNT 3136
 INCL INCLM: 514/222.500
 INCLS: 514/223.500; 514/224.500;
 514/226.800; 514/227.500;
 514/228.800; 514/229.200;
 514/230.500; 514/230.800;
 514/237.800; 514/248.000;
 514/249.000; 514/255.000;
 514/258.000; 514/274.000;
 514/301.000; 514/303.000;
 514/311.000; 514/351.000;
 514/360.000; 514/361.000;
 514/362.000; 514/363.000;
 514/364.000; 514/365.000;
 514/367.000; 514/372.000;
 514/373.000; 514/374.000;
 514/375.000; 514/376.000;
 514/378.000; 514/379.000;
 514/380.000; 514/387.000;
 514/395.000; 514/415.000;
 514/418.000; 514/424.000;
 514/425.000; 514/433.000;
 514/452.000; 514/432.000;
 514/438.000; 346/113.000;
 346/114.000; 346/164.000;
 346/300.000; 549/014.000;
 549/050.000; 549/075.000;
 549/367.000; 549/368.000;
 544/002.000; 544/003.000;
 544/005.000; 544/008.000;
 544/053.000; 544/063.000;
 544/065.000; 544/066.000;
 544/067.000; 544/090.000;
 544/091.000; 544/127.000;
 544/128.000; 544/162.000;
 544/215.000; 544/219.000;
 544/229.000; 544/235.000;
 544/237.000; 544/255.000;
 544/278.000; 544/311.000;
 544/353.000; 544/385.000;
 548/123.000; 548/125.000;
 548/131.000; 548/134.000;
 548/143.000; 548/146.000;
 548/153.000; 548/174.000;
 548/207.000; 548/214.000;
 548/215.000; 548/217.000;
 548/221.000; 548/228.000;
 548/229.000; 548/237.000;

548/240.000; 548/241.000;
548/243.000; 548/247.000;
548/267.200; 548/303.700;
548/307.100; 548/453.000;
548/486.000; 548/543.000;
548/546.000
NCL NCLM: 514/222.500
NCLS: 514/223.500; 514/224.500;
514/226.800; 514/227.500;
514/228.800; 514/229.200;
514/230.500; 514/230.800;
514/237.800; 514/248.000;
514/249.000; 514/255.000;
514/258.000; 514/274.000;
514/301.000; 514/303.000;
514/311.000; 514/351.000;
514/360.000; 514/361.000;
514/362.000; 514/363.000;
514/364.000; 514/365.000;
514/367.000; 514/372.000;
514/373.000; 514/374.000;
514/375.000; 514/376.000;
514/378.000; 514/379.000;
514/380.000; 514/387.000;
514/395.000; 514/415.000;
514/418.000; 514/424.000;
514/425.000; 514/432.000;
514/433.000; 514/438.000;
514/452.000; 544/002.000;
544/003.000; 544/005.000;
544/008.000; 544/053.000;
544/063.000; 544/065.000;
544/066.000; 544/067.000;
544/090.000; 544/091.000;
544/127.000; 544/128.000;
544/162.000; 544/215.000;
544/219.000; 544/229.000;
544/235.000; 544/237.000;
544/255.000; 544/278.000;
544/311.000; 544/353.000;
544/385.000; 546/113.000;
546/114.000; 546/164.000;
546/300.000; 548/123.000;
548/125.000; 548/131.000;
548/134.000; 548/143.000;
548/146.000; 548/153.000;
548/174.000; 548/207.000;
548/214.000; 548/215.000;
548/217.000; 548/221.000;
548/228.000; 548/229.000;
548/237.000; 548/240.000;
548/241.000; 548/243.000;
548/247.000; 548/267.200;
548/303.700; 548/307.100;
548/453.000; 548/486.000;
548/543.000; 548/546.000;
549/014.000; 549/050.000;
549/075.000; 549/367.000;
549/368.000
IC [6]
ICM: A61K031-385
ICS: A61K031-445; A61K031-47; A61K031-
505
EXF 549/75; 549/50; 549/14; 549/367;
549/368; 514/432; 514/438;
514/222.5; 514/223.5; 514/224.5;
514/226.8; 514/227.5; 514/228.8;
514/229.2; 514/230.5; 514/230.8;
514/237.8; 514/248; 514/249;
514/255; 514/258; 514/274; 514/301;
514/303; 514/311; 514/351;
514/360; 514/361; 514/362; 514/363;
514/364; 514/365; 514/367;
514/372; 514/373; 514/374; 514/375;
514/376; 514/378; 514/379;

514/380; 514/387; 514/395; 514/415;
514/418; 514/424; 514/425;
514/433; 514/452; 544/2; 544/3; 544/5;
544/8; 544/53; 544/63;
544/65; 544/66; 544/67; 544/90;
544/91; 544/127; 544/128; 544/162;
544/215; 544/219; 544/229; 544/235;
544/237; 544/255; 544/278;
544/311; 544/353; 544/385; 546/113;
546/114; 546/164; 546/300;
548/123; 548/125; 548/131; 548/134;
548/145; 548/146; 548/153;
548/174; 548/207; 548/214; 548/215;
548/217; 548/221; 548/228;
548/229; 548/237; 548/240; 548/241;
548/243; 548/247; 548/267.2;
548/303.7; 548/307.1; 548/453;
548/486; 548/543; 548/546
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 292 USPATFULL
AN 1998:128224 USPATFULL
TI Antiproliferative protein from
Bacillus thuringiensis var.
thuringiensis
IN Aggarwal, Bharat B., Houston, TX,
United States
Rodriguez-Padilla, Cristina,
Monterrey, Mexico
PA Research Development Corporation,
Carson City, NV, United States
(U.S. corporation)
Universidad Autonoma de Nuevo Leon,
Nuevo Leon, Mexico (non-U.S.
corporation)
PI US 5824636 981020
AI US 96-743553 961104 (8)
RLI Continuation of Ser. No. US 95-454636,
filed on 31 May 1995, now
abandoned
DT Utility
LN.CNT 823
INCL INCLM: 514/002.000
INCLS: 530/350.000
NCL NCLM: 514/002.000
NCLS: 530/350.000
IC [6]
ICM: A61K039-07
ICS: A61K038-16; C07K014-32
EXF 530/350; 514/2; 424/93.461
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e greene john/au

E1 1 GREENE JOEL C/AU
E2 1 GREENE JOHATHAN W/AU
E3 2 --> GREENE JOHN/AU
E4 3 GREENE JOHN D/AU
E5 1 GREENE JOHN F/AU
E6 1 GREENE JOHN L/AU
E7 4 GREENE JOHN M/AU
E8 2 GREENE JOHN P/AU
E9 1 GREENE JONATHAN/AU
E10 1 GREENE JONATHAN A/AU
E11 11 GREENE JONATHAN W/AU
E12 1 GREENE JOSEPH E/AU

=> s e7 and 11

4 "GREENE JOHN M"/AU
L3 0 "GREENE JOHN M"/AU AND L1

=> e greene j/au

E1 1 GREENE IRWIN D/AU

E2 1 GREENE IRWIN R/AU
E3 0 --> GREENE J/AU
E4 1 GREENE J JERROLD/AU
E5 2 GREENE JACK C/AU
E6 1 GREENE JACK E/AU
E7 2 GREENE JACK T/AU
E8 3 GREENE JAMES A/AU
E9 1 GREENE JAMES ALBERT/AU
E10 1 GREENE JAMES B/AU
E11 1 GREENE JAMES D/AU
E12 1 GREENE JAMES E/AU

=> e green jo/au

E1 1 GREENE JERRY/AU
E2 1 GREENE JIMMY D/AU
E3 0 --> GREENE JO/AU
E4 1 GREENE JOE A/AU
E5 1 GREENE JOEL C/AU
E6 1 GREENE JOHATHAN W/AU
E7 2 GREENE JOHN/AU
E8 3 GREENE JOHN D/AU
E9 1 GREENE JOHN F/AU
E10 1 GREENE JOHN L/AU
E11 4 GREENE JOHN M/AU
E12 2 GREENE JOHN P/AU

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT
LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
37.55 37.70

STN INTERNATIONAL LOGOFF AT 00:30:26 ON 23
NOV 1998